{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:37:31Z","timestamp":1789576651956,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012774","name":"Innovation Fund Denmark","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Danish Research Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Extracellular matrix (ECM) remodeling of the skin is a continuous process necessary for maintaining tissue homeostasis. Type VI collagen (COL6) is characterized as a beaded filament, located in the dermal ECM, where COL6-\u03b16-chain has been demonstrated upregulated in atopic dermatitis. The aim of this study was to develop and validate a competitive ELISA, targeting the N-terminal of COL6-\u03b16-chain, named C6A6, and evaluate its associations with the dermatological condition\u2019s atopic dermatitis, psoriasis, hidradenitis suppurativa, systemic lupus erythematosus, systemic sclerosis, urticaria, vitiligo, and cutaneous malignant melanoma in comparison, to healthy controls. A monoclonal antibody was raised and employed in an ELISA assay. The assay was developed, technically validated, and evaluated in two independent patient cohorts. Cohort 1 showed C6A6 was significantly elevated in patients with atopic dermatitis (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), psoriasis (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), hidradenitis suppurativa (<jats:italic>p<\/jats:italic>\u2009=\u20090.0095), systemic lupus erythematosus (<jats:italic>p<\/jats:italic>\u2009=\u20090.0032) and melanoma (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) compared to healthy donors. Cohort 2 confirmed C6A6 being upregulated in atopic dermatitis compared to healthy controls (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), but also associated with disease severity (SCORAD, <jats:italic>p<\/jats:italic>\u2009=\u20090.046) and lowered in patients receiving calcineurin inhibitors (<jats:italic>p<\/jats:italic>\u2009=\u20090.014). These findings are hypothesis generating, and the utility of the C6A6 biomarker for disease severity and treatment response needs to be validated in larger cohorts and longitudinal studies.<\/jats:p>","DOI":"10.1038\/s41598-023-28746-2","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T15:43:13Z","timestamp":1677253393000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A fragment of type VI collagen alpha-6 chain is elevated in serum from patients with atopic dermatitis, psoriasis, hidradenitis suppurativa, systemic lupus erythematosus and melanoma"],"prefix":"10.1038","volume":"13","author":[{"given":"Signe","family":"Holm Nielsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Port","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilie","family":"M\u00f8ller Hausgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper Gr\u00f8nlund","family":"Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Thyssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solveig Skovlund","family":"Groen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valdemar Wendelboe","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Egeberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Christine","family":"Bay-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon Francis","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,21]]},"reference":[{"key":"28746_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/all.12351","volume":"69","author":"D Simon","year":"2014","unstructured":"Simon, D., Aeberhard, C., Erdemoglu, Y. & Simon, H. U. Th17 cells and tissue remodeling in atopic and contact dermatitis. Allergy 69, 125\u2013131 (2014).","journal-title":"Allergy"},{"key":"28746_CR2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/14789450.2020.1773261","volume":"17","author":"J Dengjel","year":"2020","unstructured":"Dengjel, J., Bruckner-Tuderman, L. & Nystr\u00f6m, A. Skin proteomics\u2013analysis of the extracellular matrix in health and disease. Expert Rev. Proteomics 17, 377\u2013391 (2020).","journal-title":"Expert Rev. Proteomics"},{"key":"28746_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1172\/JCI93555","volume":"128","author":"MD Lynch","year":"2018","unstructured":"Lynch, M. D. & Watt, F. M. Fibroblast heterogeneity: Implications for human disease. J. Clin. Invest. 128, 26\u201335 (2018).","journal-title":"J. Clin. Invest."},{"key":"28746_CR4","first-page":"3525","volume":"128","author":"M Cescon","year":"2015","unstructured":"Cescon, M., Gattazzo, F., Chen, P. & Bonaldo, P. Collagen VI at a glance. J. Cell Sci. 128, 3525\u20133531 (2015).","journal-title":"J. Cell Sci."},{"key":"28746_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12860-021-00395-1","volume":"22","author":"MFMG Wagner","year":"2021","unstructured":"Wagner, M. F. M. G., Theodoro, T. R., Filho, C. D. A. S. M., Oyafuso, L. K. M. & Pinhal, M. A. S. Extracellular matrix alterations in the skin of patients affected by psoriasis. BMC Mol. Cell Biol. 22, 1 (2021).","journal-title":"BMC Mol. Cell Biol."},{"key":"28746_CR6","doi-asserted-by":"publisher","first-page":"5910","DOI":"10.1038\/s41598-020-62474-1","volume":"10","author":"S Holm Nielsen","year":"2020","unstructured":"Holm Nielsen, S. et al. A fragment of collagen type VI alpha-3 chain is elevated in serum from patients with gastrointestinal disorders. Sci. Rep. 10, 5910 (2020).","journal-title":"Sci. Rep."},{"key":"28746_CR7","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3109\/03008207.2013.822865","volume":"54","author":"J Fitzgerald","year":"2013","unstructured":"Fitzgerald, J., Holden, P. & Hansen, U. The expanded collagen VI family: New chains and new questions. Connect. Tissue Res. 54, 345\u2013350 (2013).","journal-title":"Connect. Tissue Res."},{"key":"28746_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/JID.2015.352","volume":"136","author":"T Georgios","year":"2016","unstructured":"Georgios, T. et al. Type VI collagen regulates dermal matrix assembly and fibroblast motility. J. Invest. Dermatol. 136, 74\u201383 (2016).","journal-title":"J. Invest. Dermatol."},{"key":"28746_CR9","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1016\/S2665-9913(20)30385-4","volume":"3","author":"R Dobrota","year":"2021","unstructured":"Dobrota, R. et al. Circulating collagen neo-epitopes and their role in the prediction of fibrosis in patients with systemic sclerosis: a multicentre cohort study. Lancet Rheumatol. 3, e175\u2013e184 (2021).","journal-title":"Lancet Rheumatol."},{"key":"28746_CR10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5021\/ad.2022.34.1.46","volume":"34","author":"HJ Jung","year":"2022","unstructured":"Jung, H. J. et al. The role of collagen VI \u03b16 chain gene in atopic dermatitis. Ann. Dermatol. 34, 46\u201354 (2022).","journal-title":"Ann. Dermatol."},{"key":"28746_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0144316","volume":"10","author":"D Ghosh","year":"2015","unstructured":"Ghosh, D. et al. Multiple transcriptome data analysis reveals biologically relevant atopic dermatitis signature genes and pathways. PLoS ONE 10, 1\u201323 (2015).","journal-title":"PLoS ONE"},{"key":"28746_CR12","doi-asserted-by":"crossref","unstructured":"Heo, W. Il et al. Identification of novel candidate variants including COL6A6 polymorphisms in early-onset atopic dermatitis using whole-exome sequencing. BMC Med. Genet. 18, (2017).","DOI":"10.1186\/s12881-017-0368-9"},{"key":"28746_CR13","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/j.1346-8138.1995.tb03428.x","volume":"22","author":"S Takasaki","year":"1995","unstructured":"Takasaki, S., Fujiwara, S., Shinkai, H. & Ooshima, A. Human type VI collagen: Purification from human subcutaneous fat tissue and an immunohistochemical study of morphea and systemic sclerosis. J. Dermatol. 22, 480\u2013485 (1995).","journal-title":"J. Dermatol."},{"key":"28746_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/BF01551818","volume":"3","author":"ML Gefter","year":"1977","unstructured":"Gefter, M. L., Margulies, D. H. & Scharff, M. D. A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells. Somatic Cell Genet. 3, 231\u2013236 (1977).","journal-title":"Somatic Cell Genet."},{"key":"28746_CR15","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00403-019-01895-z","volume":"311","author":"JG Holm","year":"2019","unstructured":"Holm, J. G., Agner, T., Clausen, M. L. & Thomsen, S. F. Determinants of disease severity among patients with atopic dermatitis: Association with components of the atopic march. Arch. Dermatol. Res. 311, 173\u2013182 (2019).","journal-title":"Arch. Dermatol. Res."},{"key":"28746_CR16","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.matbio.2017.12.008","volume":"71\u201372","author":"SR Lamand\u00e9","year":"2018","unstructured":"Lamand\u00e9, S. R. & Bateman, J. F. Collagen VI disorders: Insights on form and function in the extracellular matrix and beyond. Matrix Biol. 71\u201372, 348\u2013367 (2018).","journal-title":"Matrix Biol."},{"key":"28746_CR17","doi-asserted-by":"publisher","first-page":"e105686","DOI":"10.1371\/journal.pone.0105686","volume":"9","author":"S Lettmann","year":"2014","unstructured":"Lettmann, S. et al. Col6a1 null mice as a model to study skin phenotypes in patients with collagen VI related myopathies: Expression of classical and novel collagen vi variants during wound healing. PLoS ONE 9, e105686 (2014).","journal-title":"PLoS ONE"},{"key":"28746_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2310\/7750.2013.13059","volume":"18","author":"C Wang","year":"2014","unstructured":"Wang, C. & Lin, A. Efficacy of topical calcineurin inhibitors in psoriasis. J. Cutan. Med. Surg. 18, 8\u201314 (2014).","journal-title":"J. Cutan. Med. Surg."},{"key":"28746_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.5114\/pdia.2013.35619","volume":"30","author":"K Gutfreund","year":"2013","unstructured":"Gutfreund, K., Bienias, W., Szewczyk, A. & Kaszuba, A. Topical calcineurin inhibitors in dermatology. Part I: Properties, method and effectiveness of drug use. Adv. Dermatol. Allergol. Dermatologii Alergol. 30, 165 (2013).","journal-title":"Adv. Dermatol. Allergol. Dermatologii Alergol."},{"key":"28746_CR20","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/j.1368-5031.2005.00587.x","volume":"59","author":"P Gisondi","year":"2005","unstructured":"Gisondi, P., Ellis, C. N. & Girolomoni, G. Pimecrolimus in dermatology: atopic dermatitis and beyond. Int. J. Clin. Pract. 59, 969\u2013974 (2005).","journal-title":"Int. J. Clin. Pract."},{"key":"28746_CR21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1067\/mjd.2002.120942","volume":"46","author":"P Nghiem","year":"2002","unstructured":"Nghiem, P., Pearson, G. & Langley, R. G. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J. Am. Acad. Dermatol. 46, 228\u2013241 (2002).","journal-title":"J. Am. Acad. Dermatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28746-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28746-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28746-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T15:43:18Z","timestamp":1677253398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28746-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,21]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["28746"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-28746-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,21]]},"assertion":[{"value":"13 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SHN, HP, CMH, MK, and ACBJ are full-time employees at Nordic Bioscience A\/S. Nord 9. Nordic Bioscience is a privately-owned, small\u2013medium-size enterprise (SME) partly focused on developing biomarkers. None of the authors received fees, bonuses, or other benefits for the work described in the manuscript. SHN, MAK, and ACBJ hold stocks in Nordic Bioscience A\/S. JGH, JPT, SSG, VWN, AE and SFT have no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3056"}}